Clinical Trials Using Nazartinib
Clinical trials are research studies that involve people. The clinical trials on this list are studying Nazartinib. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
-
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in adult patients with advanced solid tumors in selected indications.
Location: 4 locations -
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.
The rollover study will provide continued treatment and assessment of long-term safety follow-up in patients receiving capmatinib (INC280) as a single agent or in combination with EGF816 or Gefitinib in a Novartis sponsored study and in the opinion of the Investigator would benefit from continued treatment.
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts -
Nazartinib and Gefitinib in Treating Patients with Recurrent or Stage IIIB-IV EGFR-Mutant Non-small Cell Lung Cancer
This phase II trial studies how well nazartinib and gefitinib work in treating patients with EGFR-mutant non-small cell lung cancer that has come back or is stage IIIB-IV. Nazartinib and gefitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts